Collection Details : HemaSphere

Journal Logo

CAR T-Cell Collection

  • Updated:   9/6/2023
  • Contains:  31 items
Following the launch of the EHA Topics-In-Focus Immunotherapy, HemaSphere is publishing articles included in a special collection titled “CAR T-Cells: Hype and Hope”. This special collection focuses on the latest developments in the field of CAR T-cell therapy.

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Bücklein, Veit; Perez, Ariel; Rejeski, Kai; More

HemaSphere. 7(8):e907, August 2023.

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA

Rejeski, Kai; Greco, Raffaella; Onida, Francesco; More

HemaSphere. 7(5):e889, May 2023.

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

Voltin, Conrad-Amadeus; Gödel, Philipp; Beckmann, Laura; More

HemaSphere. 7(1):e817, January 2023.

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival

Winkelmann, Michael; Rejeski, Kai; Blumenberg, Viktoria; More

HemaSphere. 6(10):e781, October 2022.

CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS

Rösler, Wiebke; Bink, Andrea; Bissig, Marina; More

HemaSphere. 6(7):e733, July 2022.

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies

Einsele, Hermann; Briones, Javier; Ciceri, Fabio; More

HemaSphere. 5(10):e642, October 2021.

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma

Stikvoort, Arwen; van der Schans, Jort; Sarkar, Subhashis; More

HemaSphere. 5(7):e596, July 2021.

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

Holthof, Lisa C.; Stikvoort, Arwen; van der Horst, Hilma J.; More

HemaSphere. 5(5):e561, May 2021.

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells

Karschnia, Philipp; Strübing, Felix; Teske, Nico; More

HemaSphere. 5(3):e533, March 2021.